Table 2.
In vitro antitumor activity of DBDFT against eight human tumors (
±SD).
| Cell lines | Inhibition (%) | |||||
| 0.1 (µmol/L) | 0.5 (µmol/L) | 1 (µmol/L) | 5 (µmol/L) | 10 (µmol/L) | ||
| SGC-7901 | DDP | 14.57±2.06 | 21.48±2.26 | 32.41±2.59 | 83.70±4.93 | 87.72±4.94 |
| DBDFT | 12.92±3.79 | 21.82±3.28 | 37.23±4.61* | 81.08±4.92 | 88.19±5.35 | |
| Hep G2 | DDP | 4.62±2.28 | 15.49±3.06 | 20.96±3.99 | 36.79±3.36 | 50.48±3.72 |
| DBDFT | 3.71±1.81 | 14.72±2.31 | 21.45±4.60 | 39.63±4.71 | 52.53±4.25 | |
| SHSY5Y | DDP | 4.47±1.08 | 11.66±2.49 | 18.91±2.40 | 35.39±2.95 | 51.18±3.72 |
| DBDFT | 3.90±2.49 | 12.68±1.41 | 20.82±3.35 | 41.18±3.38* | 49.39±3.16 | |
| HEC-1-B | DDP | 7.32±2.56 | 18.39±3.62 | 39.77±4.30 | 60.61±5.12 | 66.35±4.98 |
| DBDFT | 12.38±4.56* | 23.97±4.50* | 43.16±2.62 | 64.09±3.09 | 71.83±7.05 | |
| EC | DDP | 4.12±2.25 | 11.98±3.86 | 22.73±3.59 | 38.71±3.17 | 58.62±5.19 |
| DBDFT | 4.83±1.83 | 15.44±2.61 | 25.12±3.67 | 41.76±3.49 | 55.67±3.57 | |
| T24 | DDP | 3.36±1.19 | 12.23±1.26 | 21.21±2.85 | 35.72±2.98 | 74.30±2.64 |
| DBDFT | 3.07±2.00 | 11.74±1.46 | 21.24±2.67 | 51.65±5.78*** | 72.33±1.15 | |
| HeLa | DDP | 3.53±1.71 | 13.78±2.01 | 22.17±2.28 | 24.64±3.23 | 26.91±4.28 |
| DBDFT | 2.59±1.98 | 13.43±1.15 | 23.32±2.03 | 34.52±4.05** | 52.34±3.96*** | |
| A549 | DDP | ---- | ---- | ---- | ---- | ---- |
| DBDFT | 3.76±2.13 | 11.54±1.76 | 22.34±2.76 | 35.47±1.56 | 50.50±2.31 | |
Note: The SD values were obtained in six independent experiments. Positive DDP group was that with cisplatin as positive contrast drug. “----” indicated that the experiment was not performed.
*
*p<0.05,
**
**p<0.01,
***
***p<0.001, DBDFT groups versus positive DDP group.
*
*p<0.05 was considered significant.